We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)

News   Sep 27, 2012

 
CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
 
 
 

RELATED ARTICLES

The Power of Collaboration: Tackling Pharmaceutical Challenges

News

In this article, we explore how pharmaceutical companies have started to embrace a more collaborative way of working as part of a movement to help overcome some of the challenges the industry is facing.

READ MORE

A Nice Reactive Ring to It

News

Researchers have introduced a new synthetic process for producing an important family of carbon-based molecules known as γ-aryl-β-ketoesters. These molecules are used in the production of many vital pharmaceuticals.

READ MORE

Prostate Cancer "Super Responders" Live for 2 Years on Immunotherapy

News

A major clinical trial shows that some men with advanced prostate cancer who have exhausted all other treatment options could live for two years or more on immunotherapy.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE